Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 16/20 | 0.35 |
| ▸ | F2 | P00734 | 3/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5784023 | 1.00 | ALDH1A1 (0.38) | ALDH1A1HPGDSMN1; SMN2F10F2 | |
| SCHEMBL5784018 | 1.00 | ALDH1A1 (0.38) | ALDH1A1HPGDSMN1; SMN2F10F2 | |
| SCHEMBL5783198 | 0.83 | ACHE (0.40) | ALDH1A1HPGDSMN1; SMN2F10F2 | |
| SCHEMBL6404781 | 0.83 | NR1I2 (0.46) | ALDH1A1HPGDSMN1; SMN2F10F2 | |
| SCHEMBL5784790 | 0.83 | NR1I2 (0.46) | ALDH1A1HPGDSMN1; SMN2F10F2 | |
| SCHEMBL5783190 | 0.83 | ACHE (0.40) | ALDH1A1HPGDSMN1; SMN2F10F2 | |
| SCHEMBL6404809 | 0.83 | NR1I2 (0.46) | ALDH1A1HPGDSMN1; SMN2F10F2 | |
| SCHEMBL6402770 | 0.83 | ACHE (0.40) | ALDH1A1HPGDSMN1; SMN2F10F2 | |
| SCHEMBL5784019 | 0.80 | — | — | |
| SCHEMBL5780260 | 0.79 | HPGD (0.41) | ALDH1A1HPGDSMN1; SMN2F10ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933295-B2 | Substituted isoindoles and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2005-08-23 | — | — | US | disclosed |
| US-20050004207-A1 | Nitrogen compounds such as N-(2-{4-[2-Amino-2-(hydroxyimino)ethyl]benzyl}-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)-5-chloro-2-thiophenecarboxamide, used as blood-coagulation factor Xa antogonists for prophylaxis of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004207-A1 | Nitrogen compounds such as N-(2-{4-[2-Amino-2-(hydroxyimino)ethyl]benzyl}-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)-5-chloro-2-thiophenecarboxamide, used as blood-coagulation factor Xa antogonists for prophylaxis of cardiovascular disorders | F2, SERPINC1, F11 | ALDH1A1 1523/4885HPGD 25/4885SMN1; SMN2 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.